TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38687693

Group type: EXPERIMENTAL
Intervention: Educational training by a multidisciplinary team at hospital discharge and follow-up phone recall for therapy adherence.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 360
Study: 38687742

Group type: EXPERIMENTAL
Intervention: Personalized physical exercise protocol based on clinical and objective assessments.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention.
Number of subjects: 100
Study: 38687741

Group type: EXPERIMENTAL
Intervention: Schroth treatment (Standard care + Schroth treatment)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (Standard care only)
Number of subjects: 124
Study: 38687981

Group type: EXPERIMENTAL
Intervention: KOKU-Nut app, engaged 3 times a week for 12 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Leaflet promoting a healthy lifestyle (Control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: KOKU-Nut app
Number of subjects: 36
Study: 38688118

Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine (0.5 mg/kg, adjusted according to individual responses)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine
Number of subjects: 26
Study: 38688164

Group type: EXPERIMENTAL
Intervention: Valacyclovir (valA)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Valganciclovir (valG)
Number of subjects: 137
Study: 38688344

Group type: EXPERIMENTAL
Intervention: miR-106a-5p
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: miR-484
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 2-miRNA panel (miR-106a-5p and miR-484)
Number of subjects: 170
Study: 38688665

Group type: EXPERIMENTAL
Intervention: Low-dose metformin (500 mg two times per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose metformin (1000 mg two times per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38688666

Group type: EXPERIMENTAL
Intervention: Quantitative cuff-leak test (qtCLT) performed within an hour of planned extubation.
Number of subjects: 900
Study: 38688674

Group type: EXPERIMENTAL
Intervention: TARANG intervention (life skills and reproductive health empowerment group-based intervention)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual services in the community (control group)
Number of subjects: 800
Study: 38688675

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg once daily as an add-on to ongoing SSRI treatment for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo once daily as an add-on to ongoing SSRI treatment for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg once daily
Number of subjects: 0
Study: 38688870

Group type: EXPERIMENTAL
Intervention: Sodium magnetic resonance imaging (23Na-MRI)
Number of subjects: 38
Study: 38688958

Group type: EXPERIMENTAL
Intervention: Video clip-integrated doctor-patient discharge discussion
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard verbal instructions (control)
Number of subjects: 144
Study: 38688998

Group type: EXPERIMENTAL
Intervention: Intranasal parent's own milk (IPOM), given ideally twice daily until 28 days of age.
Number of subjects: 37
Study: 38689060

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nivolumab and relatlimab (anti-LAG-3)
Number of subjects: 60
Study: 38689167

Group type: EXPERIMENTAL
Intervention: Self-assessment questionnaires about CRF, sleep disturbances, and emotional symptoms; accelerometer for physical activity and sleep quality; cognitive, neuromuscular, and exercise metabolism evaluations.
Number of subjects: 65
Study: 38689218

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 66
Study: 38689233

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 108

Group type: COMPARATOR
Intervention: No BCG vaccination (BCG-naïve)
Number of subjects: 108
Study: 38689245

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 38689256

Group type: EXPERIMENTAL
Intervention: Concentrated exposure treatment (cET) delivered during four consecutive days
Number of subjects: 163
Study: 38689269

Group type: EXPERIMENTAL
Intervention: ddPCR-MRD positive patients (non-DTA genes)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combination of ddPCR with multiparameter flow cytometry (MFC)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: ddPCR-MRD positivity of non-DTA genes
Number of subjects: 152
Study: 38689304

Group type: EXPERIMENTAL
Intervention: Targeted BEP provision based on baseline nutritional status (Arm 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted BEP supplementation based on baseline nutritional status and monthly gestational weight gain monitoring (Arm 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Arm 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Universal BEP provision (Arm 4)
Number of subjects: 0
Study: 38689310

Group type: EXPERIMENTAL
Intervention: Intermittent IV paracetamol
Number of subjects: 194

Group type: COMPARATOR
Intervention: Continuous morphine
Number of subjects: 194
Study: 38689313

Group type: EXPERIMENTAL
Intervention: Capnodynamic method for measuring end-expiratory lung volume (EELVCO)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Absolute and corrected EELVCT
Number of subjects: 46
Study: 38689324

Group type: EXPERIMENTAL
Intervention: Massage therapy treatments (up to five massages within a 4-month period)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Massage therapy treatments
Number of subjects: 75
Study: 38689346

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 234
Study: 38689402

Group type: EXPERIMENTAL
Intervention: Subdissociative ketamine infusion (KI)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 300
Study: 38689404

Group type: EXPERIMENTAL
Intervention: Various preoperative, intraoperative, and postoperative risk factors for CSA-AKI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other diagnostic biomarkers
Number of subjects: 0
Study: 38689737

Group type: EXPERIMENTAL
Intervention: Phthalates (specifically Monobenzyl phthalate - MBzP)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Phthalates (MnBP and DiNP)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Phenols and phthalates (as a mixture)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Phthalate metabolites
Number of subjects: 426
Study: 38689774

Group type: EXPERIMENTAL
Intervention: COVID period (including lockdown periods)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Before COVID
Number of subjects: 374
Study: 38689829

Group type: EXPERIMENTAL
Intervention: Awake prone position (APP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 61
Study: 38690606

Group type: EXPERIMENTAL
Intervention: AZD9567 72 mg daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: AZD9567 40 mg daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prednisolone 40 mg daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prednisolone 20 mg daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prednisolone 5 mg daily
Number of subjects: 46
Study: 38690659

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 38690733

Group type: EXPERIMENTAL
Intervention: Early upregulation of immunosuppressive metabolites and elevated levels of inflammatory cytokines, signatures of coagulation, formation of neutrophil extracellular traps, and T cell functional dysregulation.
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Reduced total plasma Igs and B cells and dysregulated IFN responsiveness among critically ill patients.
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Balance disruption between IFN-stimulated genes and IFN inhibitors.
Number of subjects: 1152
Study: 38690892

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 999

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 999
Study: 38690929

Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability (BPV) measured as Standard Deviation (SD) and Average Real Variability (ARV)
Number of subjects: 5700

Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability (BPV) measured as Average Real Variability (ARV) and Standard Deviation (SD)
Number of subjects: 5700

Group type: COMPARATOR
Intervention: Intensive blood pressure control
Number of subjects: 5700
Study: 38691209

Group type: EXPERIMENTAL
Intervention: Leucocyte-platelet-rich fibrin (L-PRF) with coronally advanced flap (CAF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG) with coronally advanced flap (CAF)
Number of subjects: 12
Study: 38691272

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 151

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study: 38691316

Group type: EXPERIMENTAL
Intervention: Palopegteriparatide treatment
Number of subjects: 82
Study: 38691346

Group type: EXPERIMENTAL
Intervention: PF-07799933
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-07799933 ± binimetinib
Number of subjects: 0
Study: 38691353

Group type: EXPERIMENTAL
Intervention: D2 + No. 10 group
Number of subjects: 526

Group type: COMPARATOR
Intervention: D2 group
Number of subjects: 526
Study: 38691387

Group type: EXPERIMENTAL
Intervention: Xanomeline-trospium chloride (maximum dose xanomeline 125 mg/trospium 30 mg)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Xanomeline-trospium chloride
Number of subjects: 256
Study: 38691408

Group type: EXPERIMENTAL
Intervention: Crowdsourced HIV partner services intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Conventional HIV partner services (control)
Number of subjects: 121
Study: 38691409

Group type: EXPERIMENTAL
Intervention: Before COVID-19
Number of subjects: 0

Group type: COMPARATOR
Intervention: During/after COVID-19
Number of subjects: 0
Study: 38691582

Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 38691622

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem progenitor cell-gene therapy (HSPC-GT)
Number of subjects: 8
Study: 38691679

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation
Number of subjects: 0
Study: 38691823

Group type: EXPERIMENTAL
Intervention: Whole-pelvic radiation therapy (WPRT)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) and radiation therapy (RT)
Number of subjects: 350
Study: 38692113

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) group therapy (n=49)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Waitlist control group (n=46)
Number of subjects: 95
Study: 38692292

Group type: EXPERIMENTAL
Intervention: Recombinant ADAMTS13 (40 IU per kilogram of body weight, administered intravenously)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard therapy (plasma-derived products)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Recombinant ADAMTS13
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 48
Study: 38692399

Group type: EXPERIMENTAL
Intervention: Emotion dysregulation (DER)
Number of subjects: 183
Study: 38692428

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) tailored for adolescents with T1D; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control curricula; specific details not provided.
Number of subjects: 0
Study: 38692511

Group type: EXPERIMENTAL
Intervention: ACT workshop (delivered in two 1.5-h sessions over two weeks)
Number of subjects: 26
Study: 38692712

Group type: EXPERIMENTAL
Intervention: Clinical pharmacologist-led intervention including a detailed discharge medication management plan, a circle of care handover and early postdischarge virtual check-up visits to 1 month with 3-month follow-up.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clinical pharmacologist-led intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 56
Study: 38692713

Group type: EXPERIMENTAL
Intervention: Virtual reality assessment method for fear of falling (FOF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaires and neurophysiological assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movement and gait parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression model analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thematic analysis of qualitative data
Number of subjects: 0
Study: 38692728

Group type: EXPERIMENTAL
Intervention: Gait-focused physiotherapy (GPT) and matching home-based exercise
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard physiotherapy (SPT) and matching home-based exercise
Number of subjects: 144
Study: 38692727

Group type: EXPERIMENTAL
Intervention: adalimumab (160 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo (saline 0.9% sodium chloride)
Number of subjects: 39
Study: 38692732

Group type: EXPERIMENTAL
Intervention: Genital InFlammation Test (GIFT)
Number of subjects: 0
Study: 38692824

Group type: EXPERIMENTAL
Intervention: DNA prime (months 0, 1, 3) with protein boost (months 6 and 8)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DNA-protein coadministration (months 0, 1, 3, 6, and 8)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 38693149

Group type: EXPERIMENTAL
Intervention: HPV vaccination and HPV-based screening
Number of subjects: 26125

Group type: EXPERIMENTAL
Intervention: Dynamic transmission modelling
Number of subjects: 26125

Group type: EXPERIMENTAL
Intervention: Baseline results
Number of subjects: 26125
Study: 38693271

Group type: EXPERIMENTAL
Intervention: Intraoral cold water spray
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no cold water spray)
Number of subjects: 110
Study: 38693314

Group type: EXPERIMENTAL
Intervention: ctDCS (2 mA for 20 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: sham ctDCS
Number of subjects: 10
Study: 38693511

Group type: EXPERIMENTAL
Intervention: Ambroxol 1800 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 38693515

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise program for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 30
Study: 38693528

Group type: EXPERIMENTAL
Intervention: App with individualized motivational text messages
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group using the smartphone PHR app
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 38693537

Group type: EXPERIMENTAL
Intervention: DSD-1VL (entry into DSD at six months after ART initiation after one suppressed viral load)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DSD-2VL (entry into DSD at six months after ART initiation after two consecutive suppressed viral loads)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DSD-1VL and DSD-2VL combined
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patient-level acceptability (clinical elements)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patient-level acceptability (non-clinical elements)
Number of subjects: 90
Study: 38693583

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (25 mg/kg), moxifloxacin (400 mg), pyrazinamide, isoniazid, aspirin (150 mg), and steroids for 2 months followed by rifampicin, isoniazid, and pyrazinamide for 4 months
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Rifampicin, isoniazid, pyrazinamide (without aspirin) for 2 months followed by rifampicin, isoniazid, and pyrazinamide for 4 months
Number of subjects: 372

Group type: COMPARATOR
Intervention: Treatment according to the National TB Elimination Program guidelines
Number of subjects: 372
Study: 38694233

Group type: EXPERIMENTAL
Intervention: Pegvaliase treatment
Number of subjects: 261
Study: 38694503

Group type: EXPERIMENTAL
Intervention: XAV-19 (150 mg)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 38694931

Group type: EXPERIMENTAL
Intervention: Prospective observational study of AHF management and outcomes
Number of subjects: 7000
Study: 38694984

Group type: EXPERIMENTAL
Intervention: 12-week home-based multicomponent exercise program (MEP)
Number of subjects: 60
Study: 38694999

Group type: EXPERIMENTAL
Intervention: IV ketamine infusions
Number of subjects: 0
Study: 38695087

Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter defibrillator (S-ICD)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Transvenous ICD (TV-ICD)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Both S-ICD and TV-ICD
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD
Number of subjects: 503
Study: 38695107

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) urine tenofovir testing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Drug-level feedback from urine testing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interpretation of urine tenofovir results
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: White coat dosing behavior
Number of subjects: 30
Study: 38695123

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 260

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 260
Study: 38695191

Group type: EXPERIMENTAL
Intervention: Social Intelligence Training (SIT) program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Attention control condition focusing on healthy living habits
Number of subjects: 200
Study: 38695310

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RBD-based VLP vaccine (LYB001) at doses of 30 or 60 µg
Number of subjects: 100

Group type: COMPARATOR
Intervention: SARS-CoV-2 RBD-based protein subunit vaccine (ZF2001, control group)
Number of subjects: 100
Study: 38695372

Group type: EXPERIMENTAL
Intervention: Turkish version of the Leg Activity Measure (Tr-LegA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tr-LegA Passive and Active Function Scales
Number of subjects: 0
Study: 38695396

Group type: EXPERIMENTAL
Intervention: Peer mentoring program for dementia caregivers
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 38695479

Group type: EXPERIMENTAL
Intervention: Lenvatinib + pembrolizumab + chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab + chemotherapy
Number of subjects: 0
Study: 38695527

Group type: EXPERIMENTAL
Intervention: Mavacamten dose-titration regimen guided by echocardiographic measures
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Simulated regimen with optimal benefit-risk profile
Number of subjects: 5
Study: 38695604

Group type: EXPERIMENTAL
Intervention: SQZ-PBMC-HPV (administered as monotherapy every 3 weeks)
Number of subjects: 18
Study: 38695613

Group type: EXPERIMENTAL
Intervention: Sealant use
Number of subjects: 2376
Study: 38695743

Group type: EXPERIMENTAL
Intervention: Predisposed HFpEF
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study: 38696027

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 1683

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Upadacitinib (both dosages)
Number of subjects: 1683
Study: 38696034

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tumor necrosis factor inhibitors (TNFi)
Number of subjects: 0
Study: 38696122

Group type: EXPERIMENTAL
Intervention: Osilodrostat (starting dose: 2 mg bid; maximum: 30 mg bid)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Osilodrostat
Number of subjects: 137
Study: 38696203

Group type: COMPARATOR
Intervention: Combined Nicotine Replacement Therapy (CNRT)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 490

Group type: COMPARATOR
Intervention: Combined Nicotine Replacement Therapy (CNRT) and Varenicline
Number of subjects: 490
Study: 38696220

Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38696221

Group type: EXPERIMENTAL
Intervention: Intranasal (R,S)-Ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38696284

Group type: EXPERIMENTAL
Intervention: XC001
Number of subjects: 32
Study: 38696406

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Care Program with Virtual Reality (MBHC-VR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Care Program (MBHC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 38696428

Group type: EXPERIMENTAL
Intervention: Actual AFOs
Number of subjects: 58

Group type: COMPARATOR
Intervention: Emulated AFOs
Number of subjects: 58
Study: 38696657

Group type: EXPERIMENTAL
Intervention: Inspiratory training, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 38696672

Group type: EXPERIMENTAL
Intervention: Ultra-Rapid Lispro Insulin with Control-IQ Technology
Number of subjects: 0
Study: 38696675

Group type: EXPERIMENTAL
Intervention: Dual-energy focal CF catheter with RF and pulsed field ablation (PFA)
Number of subjects: 149
Study: 38696701

Group type: EXPERIMENTAL
Intervention: Male cohort (S-ICD recipients)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Female cohort (S-ICD recipients)
Number of subjects: 374
Study: 38696724

Group type: EXPERIMENTAL
Intervention: Comprehensive medically tailored meals, groceries, and nutritional education
Number of subjects: 191

Group type: COMPARATOR
Intervention: POH 'standard of care' food services
Number of subjects: 191